Purification method of protein-nucleic acid conjugate

CN118922538APending Publication Date: 2024-11-08NANJING GENSCRIPT BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030137.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-07-25
Filing Date
2023-07-25
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing technology has problems in the purification process of protein-nucleic acid conjugates, such as cumbersome operations and insufficient specificity for different proteins and modification types. In particular, the purification of unmodified protein macromolecules is difficult and the commonly used chromatography method is time-consuming. And not convenient.

Method used

By modifying the affinity tag onto the protein-nucleic acid conjugate and utilizing the interaction of the affinity tag with the affinity carrier, highly specific purification of the protein-nucleic acid conjugate can be achieved, including the use of Flag tags and biotin. Tags are combined and separated from corresponding carriers.

Benefits of technology

It achieves convenient operation and high-specific purification, can effectively separate protein-nucleic acid conjugates and unmodified raw materials, and improves purification efficiency and pertinence.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000026_0000
    Figure 00000026_0000
  • Figure 00000026_0001
    Figure 00000026_0001
  • Figure 00000027_0000
    Figure 00000027_0000
Patent Text Reader

Abstract

Relates to a biological coupling technology, in particular to a purification method of a protein-nucleic acid conjugate, and provides a protein-nucleic acid conjugate modified by an affinity tag, and the protein-nucleic acid conjugate is purified by utilizing the interaction of the affinity tag and an affinity carrier. The protein-nucleic acid conjugate purification method has high specificity for different proteins and modification types.
Need to check novelty before this filing date? Find Prior Art

Description

A method for purifying protein-nucleic acid conjugates

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to Chinese patent application No. CN202210880587.4 filed on July 25, 2022, the entire contents of which are incorporated herein by reference. Technical Field

[0003] The present invention relates to bioconjugation technology, and more specifically, to a method for purifying protein-nucleic acid conjugates. Specifically, the present invention provides a protein-nucleic acid conjugate modified with an affinity tag, and utilizes the interaction between the affinity tag and an affinity carrier to purify the protein-nucleic acid conjugate product. The protein-nucleic acid conjugate purification method of the present invention exhibits high specificity for different proteins and modification types. Background Art

[0004] Protein-nucleic acid conjugates have both the multifunctionality of protein molecules and the high sensitivity and selectivity of nucleic acids, and have broad application prospects in the biological field (Chemical Society Reviews 2011, 40 (12), 5910-5921). However, unlike the reaction between small molecules, the chemical modification of most proteins is difficult to complete due to steric hindrance or adjacent group effects. This also leads to a certain amount of unmodified raw materials still existing in the final reaction system (Angewandte Chemie 2010, 49 (7), 1200-1216). In order to avoid interference from these unmodified raw materials in subsequent applications, additional purification methods are required to separate the target conjugated products from the reaction mixture. For unmodified small molecules, peptides and nucleic acids, ultrafiltration cut-off devices can be used based on molecular weight differences to achieve effective removal (Small 2013, 9 (18), 3088-3091). For unmodified protein macromolecules, the commonly used method is chromatographic separation. Ion exchange chromatography (STAR ​​Protoc 2021, 2(2), 100591-100591) and hydrophobic interaction chromatography (Biotechnol Bioeng 2007, 97(2), 367-376) both have different application scenarios, but chromatographic methods have disadvantages such as being cumbersome and time-consuming.

[0005] Therefore, there is an urgent need in the art for a novel protein-nucleic acid conjugate purification method that is highly specific for different proteins and modification types.

[0006] Summary of the Invention

[0007] The present invention aims to provide a method for purifying protein-nucleic acid conjugates. This method involves attaching an affinity tag to the protein-nucleic acid conjugate, which is then bound to an affinity support via the affinity tag. This method allows the protein-nucleic acid conjugate to be separated from unmodified raw materials, such as small molecules, polypeptides, and nucleic acids, thereby purifying the protein-nucleic acid conjugate. Compared to prior art purification methods, such as chromatography, the method of the present invention offers the advantages of ease of operation and high specificity for different proteins and modification types.

[0008] In one aspect, the present invention provides a method for purifying a protein-nucleic acid conjugate, comprising the following steps:

[0009] (1) reacting the affinity-tagged nucleic acid with a protein moiety-linker conjugate as shown in formula (I) to obtain an affinity-tagged protein-nucleic acid conjugate;

[0010] (2) purifying the protein-nucleic acid conjugate obtained in step (1) using an affinity carrier capable of binding to the affinity tag;

[0011] wherein R1 is selected from hydrogen, a hydrocarbon group, an amine group, an amino group, a hydroxyl group, and a carboxyl group; the hydrocarbon group optionally has one or more substituents selected from a hydrocarbon group, an amine group, an amino group, a hydroxyl group, and a carboxyl group; the hydrocarbon group is preferably an alkyl group, an aryl group, or a combination thereof; wherein the alkyl group optionally has one or more substituents selected from an aryl group, an amine group, an amino group, a hydroxyl group, and a carboxyl group; the aryl group optionally has one or more substituents selected from an alkyl group, an amine group, an amino group, a hydroxyl group, and a carboxyl group; or R1 is selected from a fluorescent group, a PEG-modified group, a biotin-modified group, a polypeptide-modified group, and a nucleic acid-modified group;

[0012] R2 is selected from the side chain portion of any natural amino acid;

[0013] R3 is selected from hydrogen, alkyl, alkoxy, hydroxy, amino, and amine;

[0014] R4 is selected from alkylene, arylene, PEG;

[0015] R5 is selected from hydrogen and alkyl;

[0016] R6 is selected from the side chain portion of any natural amino acid.

[0017] In some embodiments, in the purification method of the present invention, the affinity tag includes a Flag tag and a biotin tag.

[0018] In some embodiments, in the purification method of the present invention, the affinity carrier is selected from resin or magnetic beads.

[0019] In some embodiments, in the purification method of the present invention, the nucleic acid is modified with a compound containing an alkyne group before step (1).

[0020] In some embodiments, in the purification method of the present invention, the nucleic acid is modified to obtain an affinity tag-modified and diphenylcyclooctyne-modified nucleic acid as shown in the following structure:

[0021] wherein n is an integer selected from 1-8.

[0022] In some embodiments, in the purification method of the present invention, the nucleic acid is selected from natural DNA; natural RNA; nucleic acids with base modifications such as 2'-F, 2'-OMe, 2'-MOE, etc.; nucleic acids with fluorescent groups, polypeptides, PEG, and phosphorylation modifications; and the nucleic acid molecules include single-stranded nucleic acids or double-stranded nucleic acids.

[0023] In some embodiments, in the purification method of the present invention, the nucleic acid has a length of 10 to 100 nt.

[0024] In some embodiments, in the purification methods of the present invention, the protein moiety-linker conjugate has the structure shown below:

[0025] In some embodiments, in the purification methods of the present invention, the protein portion is an antibody or a fragment thereof.

[0026] In some embodiments, in the purification method of the present invention, the molecular weight of the protein portion ranges from 8 kDa to 160 kDa.

[0027] In some embodiments, in the purification method of the present invention, step (2) comprises the following steps:

[0028] (2a) binding the affinity tag-modified protein-nucleic acid conjugate to an affinity carrier, thereby obtaining an affinity carrier bound to the protein-nucleic acid conjugate;

[0029] (2b) separating the affinity carrier bound to the protein-nucleic acid conjugate obtained in step (2a);

[0030] (2c) The protein-nucleic acid conjugate is detached from the affinity carrier, thereby obtaining a purified protein-nucleic acid conjugate.

[0031] In some embodiments, in the purification method of the present invention, the method for separating the protein-nucleic acid conjugate from the affinity carrier is selected from elution or photocleavage.

[0032] In one aspect, the present invention provides an affinity-tagged modified protein-nucleic acid conjugate having the following structure:

[0033] wherein R1 is selected from hydrogen, a hydrocarbon group, an amine group, an amino group, a hydroxyl group, and a carboxyl group; the hydrocarbon group optionally has one or more substituents selected from a hydrocarbon group, an amine group, an amino group, a hydroxyl group, and a carboxyl group; the hydrocarbon group is preferably an alkyl group, an aryl group, or a combination thereof; wherein the alkyl group optionally has one or more substituents selected from an aryl group, an amine group, an amino group, a hydroxyl group, and a carboxyl group; the aryl group optionally has one or more substituents selected from an alkyl group, an amine group, an amino group, a hydroxyl group, and a carboxyl group; or R1 is selected from a fluorescent group, a PEG-modified group, a biotin-modified group, a polypeptide-modified group, and a nucleic acid-modified group;

[0034] R2 is selected from the side chain portion of any natural amino acid;

[0035] R3 is selected from hydrogen, alkyl, alkoxy, hydroxy, amino, and amine;

[0036] R4 is selected from alkylene, arylene, PEG;

[0037] R5 is selected from hydrogen and alkyl;

[0038] R6 is selected from the side chain portion of any natural amino acid;

[0039] n is an integer selected from 1-8.

[0040] In some embodiments, the affinity-tagged protein-nucleic acid conjugate of the present invention has the following structure:

[0041] In some embodiments, in the affinity-tagged protein-nucleic acid conjugate of the present invention, the protein portion is an antibody or a fragment thereof.

[0042] In some embodiments, in the affinity-tagged protein-nucleic acid conjugates of the present invention, the molecular weight of the protein portion ranges from 8 kDa to 160 kDa.

[0043] In some embodiments, in the affinity-tagged protein-nucleic acid conjugates of the present invention, the nucleic acid is selected from natural DNA; natural RNA; nucleic acids with base modifications such as 2'-F, 2'-OMe, 2'-MOE, etc.; nucleic acids with fluorescent groups, polypeptides, PEG, and phosphorylation modifications; and the nucleic acid molecules include single-stranded nucleic acids or double-stranded nucleic acids.

[0044] In some embodiments, in the affinity-tagged protein-nucleic acid conjugate of the present invention, the nucleic acid has a length of 10 to 100 nt.

[0045] In some embodiments, in the affinity-tagged protein-nucleic acid conjugate of the present invention, the affinity tag is selected from a Flag tag or a biotin tag. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Figure 1: (a) Schematic diagram of the synthesis of Flag tag-modified nucleic acids; (b) Schematic diagram of the synthesis of PC-biotin-modified nucleic acids; (c) Schematic diagram of affinity purification based on bifunctional modified oligonucleotides and protein conjugates.

[0047] Figure 2: (a) Mass spectrum of MBP protein raw material; (b) Mass spectrum of nucleic acid raw material modified with DBCO at the 5' end and Flag tag at the 3' end; (c) Mass spectrum of the MBP protein-linker binding site; (d) Mass spectrum of the MBP protein-nucleic acid coupling reaction; (e) SDS-page characterization: L1: protein electrophoresis molecular weight standard; L2: MBP protein raw material; L3: MBP and Flag tag modified nucleic acid coupling reaction solution.

[0048] Figure 3: (a) Mass spectrum of MBP protein raw material; (b) Mass spectrum of nucleic acid raw material modified with PC-biotin (biotin) at the 5' end and DBCO at the 3' end; (c) Mass spectrum of the MBP protein-linker binding mass spectrum; (d) Mass spectrum of the MBP protein-nucleic acid coupling reaction; (e) SDS-page characterization: L1: protein electrophoresis molecular weight standard; L2: MBP protein raw material; L3: MBP and PC-biotin (biotin) modified nucleic acid coupling reaction solution.

[0049] Figure 4: (a) Gel image representation of resin purification of MBP protein-nucleic acid conjugate, L1: MBP protein-nucleic acid coupling reaction solution; L2: eluate after resin purification of L1 sample; (b) Gel image representation of resin purification of GFP protein-nucleic acid conjugate, L1: GFP protein-nucleic acid coupling reaction solution; L2: eluate after resin purification of L1 sample.

[0050] Figure 5: (a) Gel image representation of the photo-section purification of MBP protein-nucleic acid conjugate; L1: protein electrophoresis molecular weight standard; L2: MBP protein raw material; L3: MBP and PC-modified nucleic acid coupling reaction solution; L4: eluate after photo-section purification of L3 sample; (b) Gel image representation of the photo-section purification of GFP protein-nucleic acid conjugate; L1: protein electrophoresis molecular weight standard; L2: GFP protein raw material; L3: GFP and PC-modified nucleic acid coupling reaction solution; L4: eluate after photo-section purification of L3 sample.

[0051] Figure 6: (a) Fluorescence spectrum of a blank sample excited at 450 nm. (b) Fluorescence spectrum of a starting GFP protein excited at 450 nm. (c) Fluorescence spectrum of a resin-purified GFP protein-nucleic acid conjugate excited at 450 nm. (d) Fluorescence spectrum of a photocleavage-purified GFP protein-nucleic acid conjugate excited at 450 nm. DETAILED DESCRIPTION

[0052] Unless otherwise defined, all scientific and technical terms used herein have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. It will be understood by those skilled in the art that the methods and materials described below are exemplary only and should not be construed as limiting the scope of the present invention.

[0053] The inventors discovered that by modifying nucleic acids with affinity tags and then undergoing a synthetic reaction, affinity-tagged protein-nucleic acid conjugates can be obtained. These affinity-tagged protein-nucleic acid conjugates can then be bound to affinity supports for purification. Compared to existing techniques, the purification method of the present invention offers the advantages of ease of use and high specificity for different proteins and modification types.

[0054] As used herein, the term "affinity tag" refers to a molecule that has an affinity for another substance under specific conditions (referred to as "binding conditions") and binds to form a specific binding pair by chemical or physical means. Complementary members of the affinity tag can be immobilized (e.g., to a chromatographic support, beads, or a flat surface) to produce an affinity support that specifically binds to the affinity tag. Labeling the compound of interest with an affinity tag allows the compound to be separated from a mixture of unlabeled compounds by affinity, such as using affinity chromatography. Exemplary affinity tags include, but are not limited to, biotin, digoxigenin, streptavidin, polyhistidine (e.g., (His) 6), glutathione-S-transferase (GST), polyglutamic acid tags, FLAG-tags, HA-tags, Myc-tags, S-tags, SBP-tags, peptides, haptens, and metal ion chelates, etc. In some embodiments, preferred affinity tags include, but are not limited to, Flag tags (also known as Flag Tag, Flagtag), biotin tags. The FLAG tag is a short peptide consisting of 8 amino acid residues, N-terminus-DYKDDDDK-C-terminus.

[0055] In the present invention, the affinity tag can be modified at the 3' end, 5' end, or any position in between. Affinity-tagged nucleic acids can be synthesized by those skilled in the art using methods known to those skilled in the art, or commercially available affinity-tagged nucleic acids can be purchased.

[0056] The nucleic acid that can be used in the method for the present invention is not particularly limited. When used in this article, the term "nucleic acid" encompasses any type of nucleic acid, refers to any polymer of nucleotides (e.g., deoxyribonucleotides, ribonucleotides) of any length, wherein containing purine and pyrimidine bases, or other natural, chemically or biochemically modified, non-natural or derived nucleotide bases. The term "non-natural nucleotides" or "modified nucleotides" refers to nucleotides comprising modified nitrogenous bases, sugar or phosphate groups, or nucleotides incorporating non-natural parts into their structure. Examples of non-natural nucleotides include dideoxynucleotides, biotinylated, aminated, deaminated, alkylated, benzylated and fluorescently labeled nucleotides. The term "nucleic acid" includes DNA and RNA, such as but not limited to genomic or chromosomal DNA, plasmid DNA, amplified DNA, cDNA, total RNA, mRNA, small RNA, etc. The term "nucleic acid" is intended to include natural DNA and / or RNA molecules, or synthetic DNA and / or RNA molecules. In the present invention, the backbone of the nucleic acid can contain sugars and phosphate groups commonly found in RNA or DNA, or modified or substituted sugars or phosphate groups. The nucleic acid can contain modified nucleotides, such as methylated nucleotides and nucleotide analogs, such as base modifications such as 2'-F, 2'-OMe, and 2'-MOE. Nucleic acids can also have other modifications, including but not limited to biotin, fluorescent groups, polypeptides, PEG, phosphorylation, and the like.

[0057] In some embodiments, nucleic acid can be obtained by separating and purifying from the cell comprising nucleic acid by natural origin.In some embodiments, nucleic acid can be obtained by chemical synthesis or other known schemes for the production of nucleic acid.In some embodiments, nucleic acid has a length of 10 to 100nt, for example, 10 to 90nt, 10 to 80nt, 10 to 70nt, 10 to 60nt, 10 to 50nt, 10 to 40nt, 10 to 30nt, a length of 10 to 20nt, for example, 10nt, 20nt, 30nt, 40nt, 50nt, 60nt, 70nt, 80nt, 90nt, the degree of 100nt, for example, the length of any integer nt between 10 to 100nt.

[0058] In the present invention, the connection between the protein and the nucleic acid is carried out via a reaction between an azide group and an alkynyl group. Therefore, it is necessary to modify the nucleic acid with a compound containing an alkynyl group. As used herein, the term "alkynyl-containing compound" refers to a compound containing one or more carbon-carbon triple bonds. Alkynyl-containing compounds include, but are not limited to, straight-chain alkyne compounds, substituted straight-chain alkyne compounds, cycloalkyne compounds, substituted cycloalkyne compounds, and the like. Nucleic acids are modified with alkynyl-containing compounds to have alkynyl substituents containing one or more carbon-carbon triple bonds.

[0059] In a preferred embodiment, the compound containing an alkynyl group is preferably dibenzocyclooctyne carboxylic acid.

[0060] In a preferred embodiment, the nucleic acid is modified to have a substituent selected from diphenylcyclooctynyl, bicyclo[6.1.0]nonynyl, and the like.

[0061] In a preferred embodiment, dibenzocyclooctyne carboxylic acid is used to obtain dibenzocyclooctyne-modified nucleic acids.

[0062] Nucleic acids modified with alkynyl groups can be obtained by those skilled in the art according to well-known methods: reacting amino-modified nucleic acids with compounds containing alkynyl groups.

[0063] In the present invention, the amino modification position can be the 3' end, 5' end, or any position between the two ends of the nucleic acid. Amino-modified nucleic acids can be synthesized by those skilled in the art according to well-known methods, or commercially available amino-modified nucleic acid products can be purchased.

[0064] In some embodiments, an amino-modified nucleic acid is reacted with an alkynyl-containing carboxylic acid compound of the following structural formula in the presence of an amine to produce an alkynyl-containing modified nucleic acid:

[0065] wherein n=1-8, such as 1-6, 1-4, such as 1, 2, 3 and 4. The choice of amine can be determined by those skilled in the art based on common knowledge, as long as it can catalyze the connection reaction between the carboxyl group and the amino group.

[0066] In a preferred embodiment, the amino-modified nucleic acid is reacted with dibenzocyclooctyne carboxylic acid of the following formula in the presence of an amine:

[0067] Dibenzocyclooctyne carboxylic acid.

[0068] In the above reaction, the nucleic acid and the alkyne-containing carboxylic acid compound are reacted at a ratio of 200:1-20:1, for example, 200:1, 150:1, 100:1, 80:1, 60:1, 40:1, or 20:1.

[0069] After the above reaction, a nucleic acid modified with an alkyne-containing group at the 3' end, the 5' end, or any position between the two ends is obtained.

[0070] There is no particular limitation on the order in which the nucleic acid is modified with an affinity tag and then modified with an alkynyl-containing group. In some embodiments, an affinity-tag-modified nucleic acid is first obtained, and then the nucleic acid is modified with an alkynyl-containing compound to obtain a nucleic acid modified with both an affinity tag and an alkynyl-containing group. In some embodiments, an alkynyl-containing group-modified nucleic acid is first obtained, and then the nucleic acid is modified with an affinity tag to obtain a nucleic acid modified with both an affinity tag and an alkynyl-containing group.

[0071] The affinity tag modification and the alkyne-containing group modification are independently located at the 3' end, the 5' end, or any position between the two ends of the nucleic acid. The affinity tag modification and the alkyne-containing group modification are not located at the 3' end or the 5' end of the nucleic acid at the same time.

[0072] In some embodiments, the affinity tag-modified and alkyne-containing group-modified nucleic acids of the present invention are nucleic acids whose 3' or 5' ends are modified with diphenylcyclooctyne as shown in the following structure:

[0073] wherein n is an integer selected from 1-8, such as an integer from 1-6, 1-4, such as 1, 2, 3 and 4.

[0074] The inventors have discovered that proteins can form protein-nucleic acid conjugates by forming a protein portion-linker conjugate having a structure as shown in the following formula (I):

[0075] wherein R1 is selected from hydrogen, a hydrocarbon group, an amine group, an amino group, a hydroxyl group, and a carboxyl group, wherein the hydrocarbon group optionally has one or more substituents selected from a hydrocarbon group, an amine group, an amino group, a hydroxyl group, and a carboxyl group. The hydrocarbon group is preferably an alkyl group, an aryl group, or a combination thereof, wherein the alkyl group optionally has one or more substituents selected from an aryl group, an amine group, an amino group, a hydroxyl group, and a carboxyl group, and the aryl group optionally has one or more substituents selected from an alkyl group, an amine group, an amino group, a hydroxyl group, and a carboxyl group, or R1 is selected from a fluorescent group, a PEG-modified group, a biotin-modified group, a polypeptide-modified group, and a nucleic acid-modified group;

[0076] R2 is selected from the side chain portion of any natural amino acid;

[0077] R3 is selected from hydrogen, alkyl, alkoxy, hydroxy, amino, and amine;

[0078] R4 is selected from alkylene, arylene, PEG;

[0079] R5 is selected from hydrogen and alkyl;

[0080] R6 is selected from the side chain portion of any natural amino acid.

[0081] In some embodiments, the hydrocarbon group selected from R1 is, for example, C1-C8 alkyl, C1-C6 alkyl, C1-C4 alkyl, preferably methyl, ethyl, propyl, butyl. The alkyl group may further have one or more identical or different C6-C 14 Substituents of aryl, amine, amino, hydroxyl and carboxyl groups.

[0082] In some embodiments, R1 is selected from hydrocarbon groups such as C6-C 14 Aryl, C6-C 12 Aryl, C6-C 10 The aryl group is preferably a phenyl group or a naphthyl group. The aryl group may further have one or more identical or different substituents selected from C1-C8 alkyl groups, amine groups, amino groups, hydroxyl groups, and carboxyl groups.

[0083] In a preferred embodiment, R1 is selected from propyl, ethylamino, propionic acid, valeric acid, anilino, benzoic acid, tolyl, and hydroxyl.

[0084] In a preferred embodiment, R2 is selected from the side chain moiety of methionine.

[0085] In some embodiments, R3 is selected from alkyl, for example, C1-C8 alkyl, C1-C6 alkyl, C1-C4 alkyl, preferably methyl, ethyl, propyl, butyl. Alkoxy is selected from C1-C8 alkoxy, C1-C6 alkoxy, C1-C4 alkoxy, preferably methoxy, ethoxy, propoxy, butoxy.

[0086] In a preferred embodiment, R3 is selected from methoxy.

[0087] In some embodiments, R4 is selected from alkylene, for example, C1-C8 alkylene, C1-C6 alkylene, C1-C4 alkylene, preferably methylene, ethylene, propylene, butylene. Arylene is for example C6-C 14 Arylene, C6-C 12 Arylene, C6-C 10 The arylene group is preferably a phenylene group.

[0088] In a preferred embodiment, R4 is selected from methylene.

[0089] In some embodiments, the alkyl group selected from R5 is, for example, C1-C8 alkyl, C1-C6 alkyl, C1-C4 alkyl, preferably methyl, ethyl, propyl, or butyl.

[0090] In a preferred embodiment, R5 is selected from methyl.

[0091] In some embodiments, R1, R3, R4, and R5 are each optionally further substituted.

[0092] In a preferred embodiment, the protein moiety-linker conjugate has the structure shown below:

[0093] As used herein, the term "hydrocarbyl" refers to a group containing only hydrogen and carbon atoms. The hydrocarbyl may contain one or more double and / or triple carbon-carbon bonds and may contain cyclic groups in combination with straight or branched groups. The hydrocarbyl may contain 1 to 20 carbon atoms. In some embodiments, the hydrocarbyl contains 1 to 20, 1 to 18, 1 to 16, 1 to 14, 1 to 12, 1 to 10, 1 to 8, 1 to 6, or 1 to 4 carbon atoms. As used herein, the hydrocarbyl includes alkyl, alkenyl, cycloalkyl, cycloalkenyl, alkynyl, aryl, and combinations thereof.

[0094] When used in this article, the term "alkyl" refers to a saturated hydrocarbon group obtained by losing a hydrogen atom from a saturated alkane. The alkyl group can be linear, branched, cyclic or a combination thereof. When the alkyl group is cyclic, it may also be referred to as a "cycloalkyl group". The alkyl group typically has 1 to 20 carbon atoms. In some embodiments, the alkyl group comprises 1 to 20, 1 to 18, 1 to 16, 1 to 14, 1 to 12, 1 to 10, 1 to 8, 1 to 6 or 1 to 4 carbon atoms. Non-limiting examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl (including n-propyl, isopropyl), butyl (including n-butyl, isobutyl, sec-butyl, tert-butyl), n-pentyl, isopentyl, n-hexyl, cyclohexyl, n-heptyl, n-octyl and ethylhexyl etc. In some embodiments, the alkyl group includes methyl, ethyl, propyl and butyl etc.

[0095] As used herein, the term "alkenyl" refers to an unsaturated hydrocarbon group obtained by losing a hydrogen atom from an unsaturated olefin, having one or more carbon-carbon double bonds. An alkenyl group typically has 1 to 20 carbon atoms. In some embodiments, an alkenyl group comprises 1 to 20, 1 to 18, 1 to 16, 1 to 14, 1 to 12, 1 to 10, 1 to 8, 1 to 6, or 1 to 4 carbon atoms. Non-limiting examples of alkenyl groups include, but are not limited to, vinyl, propenyl, butenyl, pentenyl, and hexenyl.

[0096] As used herein, the term "alkynyl" refers to an unsaturated hydrocarbon group obtained by losing a hydrogen atom from an unsaturated alkyne, which has one or more carbon-carbon triple bonds. Alkynyl groups typically have 1 to 20 carbon atoms. In some embodiments, alkynyl groups comprise 1 to 20, 1 to 18, 1 to 16, 1 to 14, 1 to 12, 1 to 10, 1 to 8, 1 to 6, or 1 to 4 carbon atoms. Non-limiting examples of alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, and hexynyl.

[0097] As used herein, the term "alkylene" refers to a saturated hydrocarbon group derived from a saturated alkane by losing two hydrogen atoms. An alkylene group can be linear, branched, cyclic, or a combination thereof. When an alkylene group is cyclic, it may also be referred to as a "cycloalkylene group." An alkylene group often has 1 to 20 carbon atoms. In some embodiments, an alkylene group comprises 1 to 20, 1 to 18, 1 to 16, 1 to 14, 1 to 12, 1 to 10, 1 to 8, 1 to 6, or 1 to 4 carbon atoms. An alkylene group can be derived from a corresponding saturated alkane by losing two hydrogen atoms on the same carbon atom or by losing one hydrogen atom on different carbon atoms. Non-limiting examples of alkyl groups include, but are not limited to, methylene (i.e., -CH2-), ethylene (i.e., -CH2CH2- or -CH(CH3)-), propylene (i.e., -CH2CH2CH2-, -CH(CH2CH3)-, or -CH(CH3)CH2-), and butylene (i.e., -CH2CH2CH2CH2-, -CH(CH3)CH2CH2-, -CH2CH(CH3)CH2-, or -CH(CH2CH3)CH2-).

[0098] When used in this article, term " alkoxy " refers to the group with formula -OR, wherein R is alkyl, and it is directly connected with oxy group.Alkyl is as defined above.Alkoxy usually has 1 to 20 carbon atoms.In some embodiments, alkoxy comprises 1 to 20, 1 to 18, 1 to 16, 1 to 14, 1 to 12, 1 to 10, 1 to 8, 1 to 6 or 1 to 4 carbon atoms.The non-limiting example of alkoxy comprises methoxy, ethoxy, propoxy (comprising n-propoxy and isopropoxy), butoxy (comprising n-butoxy, isobutoxy, sec-butoxy and tert-butoxy), pentyloxy, hexyloxy etc.In some embodiments, alkoxy comprises methoxy, ethoxy, propoxy and butoxy etc.

[0099] As used herein, the term "aryl" refers to an aromatic group comprising one ring or two or three fused rings. An aryl group may have one to five rings attached to or fused to the aromatic ring. Other ring structures may be aromatic, non-aromatic, or a combination thereof. An aryl group may have 6 to 20 carbon atoms. In some embodiments, an aryl group comprises 6 to 18, 6 to 16, 6 to 14, 6 to 12, or 6 to 10 carbon atoms. Non-limiting examples of aryl groups include, but are not limited to, phenyl, biphenyl, terphenyl, anthracenyl, naphthyl, acenaphthenyl, anthraquinone, indenyl, isoindenyl, indanyl, phenanthrenyl, anthracenyl, pyrenyl, and fluorenyl. An aryl group may optionally be substituted with halogen, C 1-6 Alkyl, C 3-10 In some embodiments, aryl groups include phenyl, naphthyl, anthracenyl, and the like.

[0100] As used herein, the term "arylene" refers to a divalent group formed by removing a hydrogen atom from the aromatic ring portion of an aryl group as described above. An arylene group may have 6-20 carbon atoms. In some embodiments, an arylene group comprises 6 to 18, 6 to 16, 6 to 14, 6 to 12, or 6 to 10 carbon atoms. In some embodiments, aryl groups include phenylene, naphthylene, and the like.

[0101] As used herein, the term "amino" refers to a group in which the hydrogen of an amino group is replaced by one or two hydrocarbon groups. Amine groups include secondary amino groups (-NHR a ) or tertiary amino group (-NR a R b , where R a and R b The amino groups may be the same or different. Non-limiting examples of amino groups include, but are not limited to, methylamino, dimethylamino, ethylamino, diethylamino, 2-propylamino, 1-propylamino, di(n-propyl)amino, di(isopropyl)amino, methyl-n-propylamino, tert-butylamino, and the like. As used herein, the term "amino" may be used interchangeably with "primary amino."

[0102] As used herein, the term "halogen" or "halo" refers to chlorine, bromine, fluorine, or iodine. The term "acyl" refers to an alkylcarbonyl or arylcarbonyl substituent. The term "acylamino" refers to an amide group attached at the nitrogen atom (i.e., R-CO-NH-). The term "carbamoyl" refers to an amide group attached at the carbonyl carbon atom (i.e., NH2-CO-). The nitrogen atom on the acylamino or carbamoyl substituent is optionally substituted. The term "sulfonamido" refers to a sulfonamide substituent attached through a sulfur or nitrogen atom. The term "amino" refers to an -NH2 group. The term "hydroxy" refers to an -OH group. The term "carboxyl" refers to a -CO2H group.

[0103] The number of carbon atoms in a hydrocarbyl group such as alkyl, alkenyl, cycloalkyl, cycloalkenyl, alkynyl, and aryl is indicated herein by the prefix "C x -C y ” or “C x-y " represents, where x is the minimum number of carbon atoms in the group and y is the maximum number of carbon atoms in the group. For example, "C1-C4 alkyl" or "C 1-4 "Alkyl" refers to an alkyl group containing 1 to 4 carbon atoms.

[0104] The protein part-linker conjugate of the invention is prepared by reacting a protein modified with an N-terminal His tag with an azide-containing 2-pyridine formaldehyde derivative and a maleimide derivative.

[0105] The protein that can be used in the method of the present invention is not particularly limited. When used in this article, the term "protein" or "protein" covers any type of protein, refers to any polymer of amino acids of any length, and therefore also covers peptides, for example, peptides containing only 2 to 100 amino acids, whereby the term "protein" or "protein" can be used interchangeably with the term "polypeptide". When used in this article, the term "protein" is generally used to describe macromolecules comprising an amino acid chain, and also describes macromolecules comprising multiple amino acid chains. In some embodiments, the present invention includes full-length proteins, fragments or domains of proteins. In addition, when used in this article, the term "protein" refers to a linear amino acid chain, or refers to an amino acid chain that has been processed and folded into a functional protein. In some embodiments, proteins can be obtained by separating and purifying from cells that naturally produce proteins, cutting with enzymes (such as proteolytic enzymes), and / or by recombinant expression of nucleic acids encoding proteins or fragments. In some embodiments, proteins of the present invention and / or their fragments can be obtained by chemical synthesis or other known schemes for producing proteins and their fragments. In some embodiments, the protein is preferably an antibody and its fragment. In some embodiments, the protein preferably has a molecular weight range of 8 kDa to 160 kDa and an isoelectric point of 5.0 to 9.5.

[0106] When used herein, the term "antibody" has a broad meaning, specifically including monoclonal antibodies (including full-length antibodies with an immunoglobulin Fc region), antibody compositions with multiple epitope specificities, multispecific antibodies (e.g., bispecific antibodies, diabodies, and single-chain molecules), and antibody fragments. The term "immunoglobulin" (Ig) is used interchangeably with "antibody" herein. Antibodies may be of any class (e.g., IgG, IgE, IgM, IgD, IgA, etc.), or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgG5, IgG6, IgG7, IgG8, IgG9, IgG10, IgG11, IgG12, IgG13, IgG14, IgG15, IgG16, IgG17, IgG18, IgG19, IgG21, IgG22, IgG33, IgG34, IgG35, IgG36, IgG37, IgG38, IgG39, IgG40, IgG41, IgG42, IgG43, IgG44, IgG45, IgG46, IgG47, IgG48, IgG49, IgG51, IgG5 2a , IgG3, IgG4, IgA1, IgA2, etc.).

[0107] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerizations, amidations) that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site.

[0108] As used herein, the term "antibody fragment" comprises a portion of an intact antibody, preferably the antigen-binding and / or variable regions of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; nanobodies; single-chain antibody molecules and multispecific antibodies formed from antibody fragments.

[0109] In the present invention, the N-terminus of a protein is modified with a short peptide containing a His tag.

[0110] In some embodiments, the His-tag-containing peptide has a sequence of Xaa-His-Xaa-His, where Xaa is any naturally occurring amino acid residue. There are no particular limitations on Xaa, which can be any naturally occurring amino acid residue. Thus, in the protein moiety-linker conjugates of the present invention, R2 and R6 can be side chain moieties of any naturally occurring amino acid.

[0111] As used herein, the term "natural amino acid" refers to any of the common, naturally occurring amino acids found in naturally occurring proteins. Examples of natural amino acids include glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tryptophan, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, and histidine.

[0112] In some embodiments, the His-tag portion of a short peptide containing a His-tag is attached to the N-terminus of the protein.

[0113] In some embodiments, residue Xaa in the short peptide containing the His tag has a free -NH2 group when attached to the N-terminus of the protein.

[0114] The short peptide containing the His tag can be linked to the N-terminus of the protein by methods known in the art, and the present application has no particular limitation thereto.

[0115] After obtaining the protein modified with the short peptide containing the His tag, it is reacted with an azide-containing 2-pyridinecarboxaldehyde derivative or a maleimide derivative to obtain the protein moiety-linker conjugate of the present invention.

[0116] In the present invention, the azide-containing 2-pyridinecarboxaldehyde derivative has the structural formula shown below:

[0117] wherein R3 is selected from hydrogen, alkyl, alkoxy, hydroxyl, amino, and amine; R4 is selected from alkylene, arylene, PEG (polyethylene glycol repeating unit, i.e., -[OCH2CH2] m -, m can be an integer of 1-20, 1-16, 1-12, 1-8, 1-6, 1-4); R7 is selected from hydrogen, alkyl, alkoxy.

[0118] R7 is optionally substituted at positions 3 and 5 of the pyridine ring. Optionally, the azide-containing 2-pyridinecarboxaldehyde derivative may have one or two identical or different R7 groups.

[0119] In some embodiments, R3 is selected from alkyl, for example, C1-C8 alkyl, C1-C6 alkyl, C1-C4 alkyl, preferably methyl, ethyl, propyl, butyl. Alkoxy is selected from C1-C8 alkoxy, C1-C6 alkoxy, C1-C4 alkoxy, preferably methoxy, ethoxy, propoxy, butoxy.

[0120] In some embodiments, R4 is selected from alkylene, for example, C1-C8 alkylene, C1-C6 alkylene, C1-C4 alkylene, preferably methylene, ethylene, propylene, butylene. Arylene is for example C6-C 14 Arylene, C6-C 12 Arylene, C6-C 10 The arylene group is preferably a phenylene group.

[0121] In some embodiments, R7 is selected from alkyl, for example, C1-C8 alkyl, C1-C6 alkyl, C1-C4 alkyl, preferably methyl, ethyl, propyl, butyl. Alkoxy is selected from alkoxy, for example, C1-C8 alkoxy, C1-C6 alkoxy, C1-C4 alkoxy, preferably methoxy, ethoxy, propoxy, butoxy.

[0122] In some embodiments, R3, R4, and R7 are each optionally further substituted.

[0123] In some embodiments, the azide-containing 2-pyridinecarboxaldehyde derivative is a 6-(azidomethyl)-2-pyridinecarboxaldehyde derivative.

[0124] In this article, 6-(azidomethyl)-2-pyridinecarboxaldehyde derivatives include 6-(azidomethyl)-2-pyridinecarboxaldehyde, and derivatives having one to multiple substituents on the pyridine ring. In some embodiments, the substituent is preferably an alkoxy group, such as a C1-C8 alkoxy group, a C1-C6 alkoxy group, a C1-C4 alkoxy group, specifically a methoxy group, an ethoxy group, etc.

[0125] In some embodiments, the 6-(azidomethyl)-2-pyridinecarboxaldehyde derivative is selected from

[0126] Synthesis of 6-(azidomethyl)-2-pyridinecarboxaldehyde derivatives can be performed by those skilled in the art using well-known methods. For example, a bromine-substituted 2-pyridinecarboxaldehyde compound can be reacted with an azide to produce an azide-containing 2-pyridinecarboxaldehyde derivative. Specifically, in some embodiments, 6-(bromomethyl)-4-methoxypyridinecarboxaldehyde can be reacted with sodium azide in a solvent such as DMF for several hours under heating to produce 6-(azidomethyl)-4-methoxypyridinecarboxaldehyde for use as an NLP.

[0127] In the present invention, the maleimide derivative has the following structure:

[0128] Wherein, R1 is selected from hydrogen, hydrocarbon, amine, amino, hydroxyl, and carboxyl, and the hydrocarbon group optionally has one or more substituents selected from hydrocarbon, amine, amino, hydroxyl, and carboxyl. The hydrocarbon group is preferably an alkyl, aryl, or a combination thereof, wherein the alkyl group optionally has one or more substituents selected from aryl, amine, amino, hydroxyl, and carboxyl, and the aryl group optionally has one or more substituents selected from alkyl, amine, amino, hydroxyl, and carboxyl, or R1 is a fluorescent group, a PEG-modified group, a biotin-modified group, a polypeptide-modified group, or a nucleic acid-modified group; and R5 is selected from hydrogen and alkyl.

[0129] In some embodiments, the hydrocarbon group selected from R1 is, for example, C1-C8 alkyl, C1-C6 alkyl, C1-C4 alkyl, preferably methyl, ethyl, propyl, butyl. The alkyl group may further have one or more identical or different C6-C 14 Substituents of aryl, amine, amino, hydroxyl and carboxyl groups.

[0130] In some embodiments, R1 is selected from hydrocarbon groups such as C6-C 14 Aryl, C6-C 12 Aryl, C6-C 10 The aryl group is preferably a phenyl group or a naphthyl group. The aryl group may further have one or more identical or different substituents selected from C1-C8 alkyl groups, amine groups, amino groups, hydroxyl groups, and carboxyl groups.

[0131] In some embodiments, the alkyl group selected from R5 is, for example, C1-C8 alkyl, C1-C6 alkyl, C1-C4 alkyl, preferably methyl, ethyl, propyl, or butyl.

[0132] In some embodiments, R1 and R5 are each optionally further substituted.

[0133] In some embodiments, examples of maleimide derivatives include the following compounds, but the present invention is not limited thereto.

[0134] The modified protein, the azide-containing 2-pyridinecarboxaldehyde derivative, and the maleimide derivative are reacted at a ratio of 1:5-60:5-40, and the reaction is continued overnight to obtain the protein portion-linker conjugate of the present invention. In some embodiments, the preferred ratio of the reactants is 1:10:5.

[0135] In some embodiments, the ratio of the azide-containing 2-pyridinecarboxaldehyde derivative to the maleimide derivative is in the range of 30:1 to 1:1, for example, 30:1, 20:1, 15:1, 12:1, 10:1, 8:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1.5:1, 1:1, etc., preferably 4:1 to 1:1, and more preferably 2:1.

[0136] In some embodiments, the reaction of the protein with the azide-containing 2-pyridinecarboxaldehyde derivative or maleimide derivative is carried out in a buffer system. Buffer systems suitable for use in the present invention include, but are not limited to, BES buffer, Bis-Tris buffer, HEPES buffer, MOPS buffer, Phos buffer, TAPS buffer, Tris buffer, and the like. In some embodiments, the buffer system is preferably a phosphate buffer system (Phos buffer).

[0137] In some embodiments, the reaction of the protein with the azide-containing 2-pyridinecarboxaldehyde derivative or maleimide derivative is carried out at pH 6.0-9.0, for example, pH 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0; pH 6.5-8.5, pH 7.0-8.0; pH 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0; preferably pH 7.2-7.8, more preferably pH 7.4, 7.5, 7.6.

[0138] In the present invention, an affinity-tagged nucleic acid is linked to a protein moiety-linker conjugate to obtain an affinity-tagged protein-nucleic acid conjugate having the following structure:

[0139] Wherein, R1, R2, R3, R4, R5, R6, and n are as defined above.

[0140] In a preferred embodiment, the affinity tag-modified protein-nucleic acid conjugate has the following structure:

[0141] In the present invention, the purification step (2) comprises the following steps:

[0142] (2a) binding the affinity tag-modified protein-nucleic acid conjugate to an affinity carrier, thereby obtaining an affinity carrier bound to the protein-nucleic acid conjugate;

[0143] (2b) separating the affinity carrier bound to the protein-nucleic acid conjugate obtained in step (2a);

[0144] (2c) The protein-nucleic acid conjugate is detached from the affinity carrier, thereby obtaining a purified protein-nucleic acid conjugate.

[0145] In the present invention, the affinity carrier capable of binding to the affinity tag is not particularly limited, and common affinity carriers familiar to those skilled in the art can be used, including, but not limited to, resins and magnetic beads. For example, in some embodiments, when the affinity tag is a Flag tag, an anti-Flag tag affinity resin, such as a commercially available anti-Flag tag affinity resin, can be used. In some embodiments, when the affinity tag is a biotin tag, streptavidin magnetic beads, such as commercially available streptavidin magnetic beads, can be used.

[0146] After being detached from the affinity support, the purified protein-nucleic acid conjugate may or may not still have an affinity tag attached, depending on the biochemical properties of the affinity tag. For example, a Flag tag remains attached to the protein-nucleic acid conjugate after detachment; whereas a biotin tag, due to the cleavage of the PC structure, separates from the protein-nucleic acid conjugate and remains on the affinity support. Those skilled in the art can determine whether to retain an affinity tag attached to the purified protein-nucleic acid conjugate based on the application needs.

[0147] The experimental conditions for binding the affinity tag-modified protein-nucleic acid conjugate to the affinity carrier can be determined by those skilled in the art based on existing technologies.

[0148] The experimental conditions for separating the affinity carrier bound to the protein-nucleic acid conjugate from the mixture can be determined by those skilled in the art based on existing technologies.

[0149] The experimental conditions for separating the protein-nucleic acid conjugate from the affinity carrier can be determined by those skilled in the art based on existing technologies.

[0150] Example

[0151] The technical solutions of the present invention are further described in detail below through examples and in conjunction with the accompanying drawings. Unless otherwise specified, the reagents used in the following examples are all conventional reagents in the art, which can be obtained commercially or prepared according to conventional methods in the art, and the specifications are laboratory pure grade; the experimental methods and experimental conditions used are all conventional experimental methods and experimental conditions in the art, and reference can be made to relevant experimental manuals, known documents or manufacturer's instructions.

[0152] instrument

[0153] The PCR instrument model was A37834, purchased from Thermo Fisher Scientific.

[0154] HPLC used LC-20AD, purchased from Shimadzu.

[0155] LC-MS was performed using a 1260 Infinity II HPLC and a 6230 TOF, both purchased from Agilent.

[0156] Example 1. Synthesis of protein-nucleic acid conjugates

[0157] In this example, a protein-nucleic acid conjugate with an affinity tag of the present invention was prepared. The proteins used in this example are maltose binding protein MBP and green fluorescent protein GFP. The amino acid sequence of the N-terminal His-tag modified protein is as follows:

[0158] MBP: (SEQ ID NO: 1)

[0159] GFP: (SEQ ID NO: 2)

[0160] The affinity tag-modified nucleic acids used in this example are respectively a nucleic acid modified with DBCO at the 5' end and a FLAG tag at the 3' end, and a nucleic acid modified with a PC-biotin tag at the 5' end and a DBCO tag at the 3' end. The specific sequences are as follows:

[0161] DBCO-D-65nt-Flag: (SEQ ID NO:3)

[0162] PC-biotin-D-16nt-DBCO: (SEQ ID NO:4)

[0163] The reaction is shown in Figure 1(c).

[0164] Experimental steps:

[0165] 1. Dilute 3 nmol of protein with 30 μL of 50 mM phosphate buffer (pH 7.4). Then add 30 nmol of 6-(azidomethyl)-4-methoxypicolinaldehyde (dissolved in 1 μL of DMSO) and 15 nmol of maleimidopropionic acid (dissolved in 1 μL of DMSO). Incubate in a PCR machine at 37°C overnight.

[0166] 2. The reaction solution was transferred to a 0.5 mL ultrafiltration tube and diluted to 500 μL with phosphate buffer. The sample was concentrated to 30 μL by centrifugation at 12,000 rpm for 10 min. The washing process was repeated three times to remove excess small molecule compounds to obtain the protein-linker conjugate.

[0167] 3. Add 4.5 nmol of affinity-tagged nucleic acid (DBCO-D-65nt-Flag or PC-biotin-D-16nt-DBCO) to 30 μL of protein-linker conjugate dissolved in 50 mM phosphate buffer (pH 7.4) and react overnight at room temperature to obtain a protein-nucleic acid conjugate.

[0168] The conjugates were characterized by mass spectrometry and SDS-PAGE gel analysis. Conjugation efficiency was calculated by integrating the optical density of the upper and lower bands in the gel image using BIO-RAD Image Lab software. The mass spectra and SDS-PAGE gel images of the reactants and products corresponding to the FLAG tag are shown in Figure 2, and the mass spectra and SDS-PAGE gel images of the reactants and products corresponding to the PC-biotin tag are shown in Figure 3.

[0169] Conclusion: Two protein-nucleic acid conjugates with FLAG and PC-biotin affinity tags, respectively, were synthesized under the above experimental conditions. Mass spectrometry results were consistent with the theoretical molecular weights. Reaction conversions were determined by SDS-PAGE and calculated by optical density integration using Bio-rad Image Lab software. The conversion rates for the FLAG-tag product were 87.5%, and for the PC-biotin-tag product were 84.3%.

[0170] Example 2. Testing of Flag-tag modified protein-nucleic acid conjugates by resin purification

[0171] In this example, a Flag tag-modified protein-nucleic acid conjugate was purified using resin. The protein-nucleic acid conjugates used in this example included the MBP protein conjugate and GFP conjugate prepared according to Example 1.

[0172] The purification process is shown in Figure 1(c).

[0173] Experimental steps:

[0174] 1. Prepare B&W buffer (50 mM Tris, 150 mM NaCl, pH 7.4) and eluent (dissolve the Flag tag peptide in the above B&W buffer at a concentration of 500 μg / mL).

[0175] 2. Add 100 μL of anti-Flag tag affinity resin (Genscript, Cat# L00432) to a 1.5 mL centrifuge tube, centrifuge and discard the supernatant. Add 0.5 mL of B&W buffer to wash the resin, pipette to mix, centrifuge and discard the supernatant. Repeat this step three times.

[0176] 3. Resuspend the washed resin in 100 μL B&W buffer, add 50 μg Flag tag-modified protein-nucleic acid conjugate, move the centrifuge tube to 4°C and incubate for 1 hour with mixing (oscillation or rotation);

[0177] 4. Centrifuge and discard the supernatant. Add 0.5 mL of B&W buffer to wash the resin. Pipet and mix thoroughly. Centrifuge and discard the supernatant. Repeat this step three times.

[0178] 5. Resuspend the treated resin in 100 μL of eluent, mix and incubate at room temperature for 5 minutes. Centrifuge after incubation. Transfer the supernatant containing the protein-nucleic acid conjugate to a centrifuge tube and store at 4°C until Qubit measurement and SDS-PAGE gel analysis. The reaction conversion rate is calculated by optical density integration using Bio-rad Image Lab software and the results are listed in Table 1 below. The SDS-PAGE gel analysis is shown in Figure 4.

[0179] Table 1. Resin purification measurement data

[0180] Conclusion: The Flag tag-modified protein-nucleic acid conjugate prepared in the present invention can be purified by the corresponding anti-Flag tag affinity resin to obtain a pure product.

[0181] Example 3. Testing of PC-biotin-modified protein-nucleic acid conjugates by photocleavage purification

[0182] In this example, the prepared protein-nucleic acid conjugate modified with PC-biotin was purified by photocleavage. The protein-nucleic acid conjugate used in this example included the MBP protein conjugate and GFP conjugate prepared according to Example 1.

[0183] The purification process is shown in Figure 1(c).

[0184] Experimental steps:

[0185] 1. Prepare B&W buffer (10 mM Tris, 1 mM EDTA, 2 M NaCl, pH 7.5);

[0186] 2. Add 100 μL of streptavidin magnetic beads (Genscript, Cat# L00424) to a 1.5 mL centrifuge tube. Place the tube on a magnetic rack to collect the beads. Remove and discard the supernatant. Add 0.5 mL of B&W buffer to wash the beads. Pipet several times to mix. Separate and discard the supernatant. Repeat this step three times.

[0187] 3. Resuspend the washed magnetic beads in 100 μL B&W buffer, add 50 μg PC-biotin-modified protein-nucleic acid conjugate, move the centrifuge tube to 4°C and incubate with mixing (oscillation or rotation) for 1 hour;

[0188] 4. Use a magnetic stand to collect the beads and discard the supernatant. Add 1 mL of B&W buffer to the tube and mix thoroughly. Use a magnetic stand to collect the beads and discard the supernatant. Repeat the washing step three times.

[0189] 5. Resuspend the treated magnetic beads in 100 μL of B&W buffer and irradiate under near-UV light in the 300-350 nm range for 1 hour. Separate the beads using a magnetic stand and transfer the supernatant containing the protein-nucleic acid conjugate to a centrifuge tube. Store at 4°C until Qubit readings and SDS-PAGE gel analysis are performed. The coupling efficiency is calculated by integrating the optical density using Bio-rad Image Lab software and is listed in Table 2 below. The SDS-PAGE gel analysis is shown in Figure 5.

[0190] Table 2. Photocatalytic purification measurement data

[0191] Conclusion: The PC-biotin-modified protein-nucleic acid conjugate prepared in the present invention can be purified by corresponding streptavidin magnetic beads to obtain a pure product.

[0192] In the following examples, the activity of the protein after purification was tested.

[0193] Example 4. MBP adsorption performance test:

[0194] In this example, the protein activities of the resin-purified and photocleavage-purified MBP protein-nucleic acid conjugates were tested and compared with the MBP protein raw material.

[0195] Experimental steps:

[0196] 1. Prepare B&W buffer (20 mM Tris, 1 mM EDTA, 1 mM DTT, 200 mM NaCl, pH 7.4) and elution buffer (dissolve maltose in the above B&W buffer to a concentration of 10 mM);

[0197] 2. Add 50 μL of resin (take two aliquots) to a 1.5 mL centrifuge tube, centrifuge and discard the supernatant, then add 0.5 mL of B&W buffer to wash the resin, pipette several times to mix, centrifuge and discard the supernatant, and repeat this step three times;

[0198] 3. Resuspend the two washed resins in 100 μL of B&W buffer. Then add 10 μg of MBP protein starting material and purified MBP protein-nucleic acid conjugate, respectively, and gently invert the tube to mix. Move the centrifuge tube to 4°C and incubate with mixing (shaking or rotating) for 1 hour.

[0199] 4. Centrifuge, retain the supernatant for measurement, add 0.5 mL of B&W buffer to the bottom resin for washing, pipette several times to mix, centrifuge and discard the supernatant, repeat this step three times;

[0200] 5. Resuspend the treated resin in 100 μL of elution buffer and incubate at room temperature for 10 minutes. Centrifuge after incubation and transfer the supernatant containing the conjugate to a centrifuge tube. Store at 4°C until the Qubit assay is completed. The results are listed in Table 3 below.

[0201] Table 3. MBP protein adsorption activity measurement data

[0202] Conclusion: The binding properties of the MBP protein-nucleic acid conjugates treated by the two purification methods were consistent with those of the MBP protein raw material.

[0203] Example 5. GFP fluorescence performance test:

[0204] In this example, the protein activity of the resin-purified and photocleavage-purified GFP protein-nucleic acid conjugates was tested and compared with the GFP protein raw material.

[0205] Experimental steps:

[0206] The excitation wavelength was set at 450 nm, and the fluorescence emission spectra of the blank sample (solvent) and the sample (solvent + test protein) were measured (emission peak wavelength ~ 535 nm). The peak areas of the scattering peak and emission peak were calculated using FL Solutions software, and the fluorescence quantum yield was calculated by substituting them into the formula. The results are listed in Table 4 below. The fluorescence spectrum is shown in Figure 6 (fluorescence quantum yield: number of emitted fluorescence photons / number of incident absorbed photons = (A_535S - A_535B) / (A_450B - A_450S), A535S: emission peak area of ​​the test sample at a wavelength of 535 nm, A535B: emission peak area of ​​the blank sample at a wavelength of 535 nm, A450B: scattering peak area of ​​the blank sample at a wavelength of 450 nm, A450S: scattering peak area of ​​the test sample at 450 nm).

[0207] Table 4. Calculation data of GFP protein fluorescence quantum yield

[0208] Conclusion: The fluorescence properties of the GFP protein-nucleic acid conjugates treated by the two purification methods were consistent with those of the GFP protein raw material.

[0209] The embodiments of the present invention are not limited to the above embodiments. Without departing from the spirit and scope of the present invention, ordinary technicians in this field can make various changes and improvements to the present invention in form and details, and these are all considered to fall within the scope of protection of the present invention.

Claims

1. A method for purifying a protein-nucleic acid conjugate, comprising the following steps: (1) reacting the affinity-tagged nucleic acid with a protein moiety-linker conjugate as shown in formula (I) to obtain an affinity-tagged protein-nucleic acid conjugate; (2) purifying the protein-nucleic acid conjugate obtained in step (1) using an affinity carrier capable of binding to the affinity tag; wherein R1 is selected from hydrogen, a hydrocarbon group, an amine group, an amino group, a hydroxyl group, and a carboxyl group; the hydrocarbon group optionally has one or more substituents selected from a hydrocarbon group, an amine group, an amino group, a hydroxyl group, and a carboxyl group; the hydrocarbon group is preferably an alkyl group, an aryl group, or a combination thereof; wherein the alkyl group optionally has one or more substituents selected from an aryl group, an amine group, an amino group, a hydroxyl group, and a carboxyl group; the aryl group optionally has one or more substituents selected from an alkyl group, an amine group, an amino group, a hydroxyl group, and a carboxyl group; or R1 is selected from a fluorescent group, a PEG-modified group, a biotin-modified group, a polypeptide-modified group, and a nucleic acid-modified group; R2 is selected from the side chain portion of any natural amino acid; R3 is selected from hydrogen, alkyl, alkoxy, hydroxy, amino, and amine; R4 is selected from alkylene, arylene, PEG; R5 is selected from hydrogen and alkyl; R6 is selected from the side chain portion of any natural amino acid.

2. The purification method according to claim 1, wherein The affinity tags include Flag tags and biotin tags.

3. The purification method according to claim 1, wherein The affinity carrier is selected from resin or magnetic beads.

4. The purification method according to any one of claims 1 to 3, wherein Prior to step (1), the nucleic acid is modified with a compound containing an alkyne group.

5. The purification method according to claim 4, wherein After the nucleic acid is modified, an affinity tag-modified and diphenylcyclooctyne-modified nucleic acid is obtained as shown in the following structure: wherein n is an integer selected from 1-8.

6. The purification method according to any one of claims 1 to 5, wherein The nucleic acid is selected from natural DNA; natural RNA; nucleic acids with base modifications such as 2'-F, 2'-OMe, 2'-MOE, etc.; nucleic acids with fluorescent groups, polypeptides, PEG, and phosphorylation modifications; and the nucleic acid molecules include single-stranded nucleic acids or double-stranded nucleic acids.

7. The purification method according to any one of claims 1 to 6, wherein The nucleic acid has a length of 10 to 100 nt.

8. The purification method according to any one of claims 1 to 7, wherein The protein moiety-linker conjugate has the structure shown below:

9. The purification method according to any one of claims 1 to 8, wherein The protein portion is an antibody or a fragment thereof.

10. The purification method according to any one of claims 1 to 9, wherein The molecular weight of the protein portion ranges from 8 kDa to 160 kDa.

11. The purification method according to any one of claims 1 to 10, wherein Step (2) includes the following steps: (2a) binding the affinity tag-modified protein-nucleic acid conjugate to an affinity carrier, thereby obtaining an affinity carrier bound to the protein-nucleic acid conjugate; (2b) separating the affinity carrier bound to the protein-nucleic acid conjugate obtained in step (2a); (2c) The protein-nucleic acid conjugate is detached from the affinity carrier, thereby obtaining a purified protein-nucleic acid conjugate.

12. The purification method according to claim 11, wherein The method of separating the protein-nucleic acid conjugate from the affinity carrier is selected from elution or photocleavage.

13. An affinity-tagged protein-nucleic acid conjugate having the structure shown below: in, R1 is selected from hydrogen, hydrocarbon, amine, amino, hydroxyl, carboxyl, the hydrocarbon optionally having one or more substituents selected from hydrocarbon, amine, amino, hydroxyl, carboxyl, the hydrocarbon is preferably an alkyl, aryl, or a combination thereof, wherein the alkyl optionally has one or more substituents selected from aryl, amine, amino, hydroxyl, carboxyl, and the aryl optionally has one or more substituents selected from alkyl, amine, amino, hydroxyl, carboxyl, or R1 is selected from a fluorescent group, a PEG modification group, a biotin modification group, a polypeptide modification group, or a nucleic acid modification group; R2 is selected from the side chain portion of any natural amino acid; R3 is selected from hydrogen, alkyl, alkoxy, hydroxy, amino, and amine; R4 is selected from alkylene, arylene, PEG; R5 is selected from hydrogen and alkyl; R6 is selected from the side chain portion of any natural amino acid; n is an integer selected from 1-8.

14. The affinity-tagged protein-nucleic acid conjugate according to claim 13, which has the following structure:

15. The affinity-tagged protein-nucleic acid conjugate according to claim 13 or 14, wherein: The protein portion is an antibody or a fragment thereof.

16. The affinity-tagged protein-nucleic acid conjugate according to any one of claims 13 to 15, wherein: The molecular weight of the protein portion ranges from 8 kDa to 160 kDa.

17. The affinity-tagged protein-nucleic acid conjugate according to any one of claims 13 to 16, wherein: The nucleic acid is selected from natural DNA; natural RNA; nucleic acids with base modifications such as 2'-F, 2'-OMe, 2'-MOE, etc.; nucleic acids with fluorescent groups, polypeptides, PEG, and phosphorylation modifications; and the nucleic acid molecules include single-stranded nucleic acids or double-stranded nucleic acids.

18. The affinity-tagged protein-nucleic acid conjugate according to any one of claims 13 to 17, wherein: The nucleic acid has a length of 10 to 100 nt. The affinity-tagged protein-nucleic acid conjugate according to any one of claims 13 to 18, wherein the affinity tag is selected from a Flag tag or a biotin tag.